ASH Letter re FDAs Draft Guidance on Myelodysplastic Syndromes

American Society of Hematology. (2025).
ASH Letter re FDAs Draft Guidance on Myelodysplastic Syndromes.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-myelodysplastic-syndromes.

American Society of Hematology.
"ASH Letter re FDAs Draft Guidance on Myelodysplastic Syndromes." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-myelodysplastic-syndromes
(label-accessed September 25, 2025).

"American Society of Hematology."
ASH Letter re FDAs Draft Guidance on Myelodysplastic Syndromes, 25 Sep. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-myelodysplastic-syndromes.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero